UTHRUNITED THERAPEUTICS Corp
Pharmaceutical Preparations
- Revenue
- $3.2B
- 11% YoY
- Operating margin
- 46.9%
- 2.0% YoY
- EBITDA
- $1.6B
- 8.9% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear117% of net incomeCash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear64% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.9B | $2.3B | $2.9B | $3.2B | 11% |
| Operating income | $556M | $980M | $1.2B | $1.4B | $1.5B | 8.4% |
| Net income | $476M | $727M | $985M | $1.2B | $1.3B | 12% |
| Operating cash flow | $598M | $803M | $978M | $1.3B | $1.6B | 18% |
| Capex | $121M | $139M | $230M | $247M | $521M | 111% |
| Stock-based comp | $139M | $107M | $39M | $144M | $148M | 2.6% |
| Buybacks | — | $0 | $0 | $1.0B | $1.0B | 0.0% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $246M · 605
- Net
- −$246M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $18M | $150M | 321 | 201 |
| FY2024 | $23M | $120M | 232 | 156 |
| FY2023 | $17M | −$11M | 145 | 144 |
| FY2022 | $5M | $41M | 183 | 139 |
| FY2021 | $4M | $50M | 142 | 124 |